Literature DB >> 21969113

Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity.

Roya Safi1, Mossa Gardaneh, Yasin Panahi, Nader Maghsoudi, Mohammad Zaefizadeh, Ehsan Gharib.   

Abstract

Optimized levels of glial cell line-derived neurotrophic factor (GDNF) are critical for protection of dopaminergic neurons against parkinsonian cell death. Recombinant lentiviruses harboring GDNF coding sequence were constructed and used to infect astrocytoma cell line 1321N1. The infected astrocytes overexpressed GDNF mRNA and secreted an average of 2.2 ng/mL recombinant protein as tested in both 2 and 16 weeks post-infection. Serial dilutions of GDNF-enriched conditioned medium from infected astrocytes added to growing neuroblastoma cell line SK-N-MC resulted in commensurate resistance against 6-OHDA toxicity. SK-N-MC cell survival rate rose from 51% in control group to 84% in the cells grown with astro-CM containing 453 pg secreted GDNF, an increase that was highly significant (P < 0.0001). However, larger volumes of the GDNF-enriched conditioned medium failed to improve cell survival and addition of volumes that contained 1,600 pg or more GDNF further reduced survival rate to below 70%. Changes in cell survival paralleled to changes in the percent of apoptotic cell morphologies. These data demonstrate the feasibility of using astrocytes as minipumps to stably oversecrete neurotrophic factors and further indicate that GDNF can be applied to neuroprotection studies in PD pending the optimization of its concentrations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21969113     DOI: 10.1007/s12031-011-9654-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  67 in total

1.  Microcapsules prepared with different biomaterials to immobilize GDNF secreting 3T3 fibroblasts.

Authors:  S Ponce; G Orive; A R Gascón; R M Hernández; J L Pedraz
Journal:  Int J Pharm       Date:  2005-04-11       Impact factor: 5.875

2.  Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease.

Authors:  Lee Anna Cunningham; Chunyan Su
Journal:  Exp Neurol       Date:  2002-04       Impact factor: 5.330

3.  Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis.

Authors:  P Riederer; S Wuketich
Journal:  J Neural Transm       Date:  1976       Impact factor: 3.575

4.  Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease.

Authors:  P Akerud; J M Canals; E Y Snyder; E Arenas
Journal:  J Neurosci       Date:  2001-10-15       Impact factor: 6.167

Review 5.  Nigrostriatal neuronal death in Parkinson's disease--a passive or an active genetically-controlled process?

Authors:  I Ziv; A Barzilai; D Offen; N Nardi; E Melamed
Journal:  J Neural Transm Suppl       Date:  1997

6.  Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor.

Authors:  N Nakao; H Yokote; K Nakai; T Itakura
Journal:  J Neurosurg       Date:  2000-04       Impact factor: 5.115

7.  Grafts of extra-adrenal chromaffin cells as aggregates show better survival rate and regenerative effects on parkinsonian rats than dispersed cell grafts.

Authors:  B Galan-Rodriguez; A del-Marco; J A Flores; S Ramiro-Fuentes; R Gonzalez-Aparicio; I Tunez; I Tasset; E Fernandez-Espejo
Journal:  Neurobiol Dis       Date:  2007-11-28       Impact factor: 5.996

8.  Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF.

Authors:  Jing Ding; Jie-Zhong Yu; Qin-Ying Li; Xin Wang; Chuan-Zhen Lu; Bao-Guo Xiao
Journal:  Brain Behav Immun       Date:  2009-05-15       Impact factor: 7.217

Review 9.  Emerging restorative treatments for Parkinson's disease.

Authors:  Tomas Deierborg; Denis Soulet; Laurent Roybon; Vanessa Hall; Patrik Brundin
Journal:  Prog Neurobiol       Date:  2008-05-14       Impact factor: 11.685

Review 10.  GDNF delivery for Parkinson's disease.

Authors:  N K Patel; S S Gill
Journal:  Acta Neurochir Suppl       Date:  2007
View more
  11 in total

Review 1.  Novel Approaches in Astrocyte Protection: from Experimental Methods to Computational Approaches.

Authors:  Daniel Garzón; Ricardo Cabezas; Nelson Vega; Marcos Ávila-Rodriguez; Janneth Gonzalez; Rosa Margarita Gómez; Valentina Echeverria; Gjumrakch Aliev; George E Barreto
Journal:  J Mol Neurosci       Date:  2016-01-23       Impact factor: 3.444

2.  Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine.

Authors:  Fernanda Martins Lopes; Giovana Ferreira Londero; Liana Marengo de Medeiros; Leonardo Lisbôa da Motta; Guilherme Antônio Behr; Valeska Aguiar de Oliveira; Mohammad Ibrahim; José Cláudio Fonseca Moreira; Lisiane de Oliveira Porciúncula; João Batista Teixeira da Rocha; Fábio Klamt
Journal:  Neurotox Res       Date:  2012-01-20       Impact factor: 3.911

3.  Glutathione transferase-M2-2 secreted from glioblastoma cell protects SH-SY5Y cells from aminochrome neurotoxicity.

Authors:  Carlos Cuevas; Sandro Huenchuguala; Patricia Muñoz; Monica Villa; Irmgard Paris; Bengt Mannervik; Juan Segura-Aguilar
Journal:  Neurotox Res       Date:  2014-11-18       Impact factor: 3.911

4.  Lenti-GDNF gene therapy protects against Alzheimer's disease-like neuropathology in 3xTg-AD mice and MC65 cells.

Authors:  Susana Revilla; Suzanna Ursulet; María Jesús Álvarez-López; Marco Castro-Freire; Unai Perpiñá; Yoelvis García-Mesa; Analía Bortolozzi; Lydia Giménez-Llort; Perla Kaliman; Rosa Cristòfol; Chamsy Sarkis; Coral Sanfeliu
Journal:  CNS Neurosci Ther       Date:  2014-08-13       Impact factor: 5.243

5.  N-cadherin is a novel ERα anchor that protects against 6-OHDA damage to dopaminergic cells.

Authors:  Meng Wang; Feng Li; Zixiao Shi; Yaping Liu; Xiaozhou Wang; Li Li; Dianshuai Gao
Journal:  Cell Mol Neurobiol       Date:  2013-11-20       Impact factor: 5.046

6.  PDGF-BB Preserves Mitochondrial Morphology, Attenuates ROS Production, and Upregulates Neuroglobin in an Astrocytic Model Under Rotenone Insult.

Authors:  Ricardo Cabezas; Nelson E Vega-Vela; Juliana González-Sanmiguel; Janneth González; Paula Esquinas; Valentina Echeverria; George E Barreto
Journal:  Mol Neurobiol       Date:  2017-05-02       Impact factor: 5.590

7.  PDGF-BB protects mitochondria from rotenone in T98G cells.

Authors:  Ricardo Cabezas; Marcos Fidel Avila; Janneth González; Ramon Santos El-Bachá; George E Barreto
Journal:  Neurotox Res       Date:  2014-12-17       Impact factor: 3.911

8.  Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction.

Authors:  Sandro Huenchuguala; Patricia Muñoz; Patricio Zavala; Mónica Villa; Carlos Cuevas; Ulises Ahumada; Rebecca Graumann; Beston F Nore; Eduardo Couve; Bengt Mannervik; Irmgard Paris; Juan Segura-Aguilar
Journal:  Autophagy       Date:  2014-01-14       Impact factor: 16.016

9.  The proform of glia cell line-derived neurotrophic factor: a potentially biologically active protein.

Authors:  Xiao-Long Sun; Bei-Yu Chen; Li Duan; Yi Xia; Zhuo-Jing Luo; Jing-Jie Wang; Zhi-Ren Rao; Liang-Wei Chen
Journal:  Mol Neurobiol       Date:  2013-08-10       Impact factor: 5.590

10.  Shikonin protects dopaminergic cell line PC12 against 6-hydroxydopamine-mediated neurotoxicity via both glutathione-dependent and independent pathways and by inhibiting apoptosis.

Authors:  Emran Esmaeilzadeh; Mossa Gardaneh; Ehsan Gharib; Farzaneh Sabouni
Journal:  Neurochem Res       Date:  2013-05-01       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.